Medicis Pharmaceutical Corp. (MRX) Misses Q3 EPS by 5c; Guides Q4 EPS Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $70.06 +2.46%
EPS Growth %: +27.1%
Financial Fact:
Depreciation and amortization: 18.32M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +27.1%
Financial Fact:
Depreciation and amortization: 18.32M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q3 EPS of $0.56, $0.05 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $184.7 million versus the consensus estimate of $187.06 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
